Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study

PLoS Medicine

Volumn 14, Issue 9, 2017, Pages

  Molokie, Robert ^a,b   Lavelle, Donald ^a,b   Gowhari, Michel ^a   Pacini, Michael ^a   Krauz, Lani ^a   Hassan, Johara ^a   Ibanez, Vinzon ^b   Ruiz, Maria A ^b   Ng, Kwok Peng ^c   Woost, Philip ^d   Radivoyevitch, Tomas ^e   Pacelli, Daisy ^a   Fada, Sherry ^c   Rump, Matthew ^c   Hsieh, Matthew ^f   Tisdale, John F ^f   Jacobberger, James ^d   Phelps, Mitch ^g   Engel, James Douglas ^h   Saraf, Santhosh ^a   Hsu, Lewis L ^a   Gordeuk, Victor ^a   DeSimone, Joseph ^a   Saunthararajah, Yogen ^c   more..

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN; CYTIDINE DEAMINASE; D DIMER; DECITABINE; DNA METHYLTRANSFERASE 1; HEMOGLOBIN F; LACTATE DEHYDROGENASE; PLACEBO; TETRAHYDROURIDINE; AZACITIDINE; ENZYME INHIBITOR;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ACUTE CHEST SYNDROME; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE CONTROL; GENE SILENCING; HEADACHE; HEMATURIA; HEMOLYSIS; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOMAGNESEMIA; INFLAMMATION; KNEE PAIN; LEG PAIN; LEUKOPENIA; MACULOPAPULAR RASH; MALE; METHYLATION; NAUSEA; NEUTROPHIL; OLIGOMENORRHEA; OTITIS; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; POLYMERIZATION; PRURITUS; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; RETICULOCYTE; SICKLE CELL ANEMIA; SINUSITIS; SKIN ULCER; SORE THROAT; SWELLING; TACHYCARDIA; THROMBOCYTE; THROMBOPHILIA; TONGUE SWELLING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WHEEZING; ANALOGS AND DERIVATIVES; ANEMIA, SICKLE CELL; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANEMIA, SICKLE CELL; AZACITIDINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; FETAL HEMOGLOBIN; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; TETRAHYDROURIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85029668221     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002382     Document Type: Article

References (119)

1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med330: 1639–1644. doi: 10.1056/NEJM199406093302303 7993409
2. Lanzkron S, Carroll CP, Haywood C, Jr. (2013) Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Reports128: 110–116. doi: 10.1177/003335491312800206 23450875
3. Goldberg MA, Husson MA, Bunn HF, (1977) Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem252: 3414–3421. 16902
4. Nagel RL, Bookchin RM, Johnson J, Labie D, Wajcman H, Isaac-Sodeye WA, et al. (1979) Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A76: 670–672. 284392
5. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. (2011) Fetal hemoglobin in sickle cell anemia. Blood118: 19–27. doi: 10.1182/blood-2011-03-325258 21490337
6. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. (1991) Pain in sickle cell disease. Rates and risk factors. N Engl J Med325: 11–16. doi: 10.1056/NEJM199107043250103 1710777
7. Powars DR, Weiss JN, Chan LS, Schroeder WA, (1984) Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?Blood63: 921–926. 6200161
8. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA289: 1645–1651. doi: 10.1001/jama.289.13.1645 12672732
9. Atweh GF, Schechter AN, (2001) Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol8: 123–130. 11224687
10. Powars DR, Elliott-Mills DD, Chan L, Niland J, Hiti AL, Opas LM, et al. (1991) Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med115: 614–620. 1892333
11. Lebensburger J, Johnson SM, Askenazi DJ, Rozario NL, Howard TH, Hilliard LM, (2011) Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. Am J Hematol86: 430–432. doi: 10.1002/ajh.21994 21523807
12. Aban I, Baddam S, Hilliard LM, Howard TH, Feig DI, Lebensburger JD, (2017) Severe anemia early in life as a risk factor for sickle-cell kidney disease. Blood129: 385–387. doi: 10.1182/blood-2016-09-738104 27919909
13. Conley CL, Weatherall DJ, Richardson SN, Shepard MK, Charache S, (1963) Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood21: 261–281. 14022587
14. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F, (1978) Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med88: 1–6. 619731
15. Ngo DA, Aygun B, Akinsheye I, Hankins JS, Bhan I, Luo HY, et al. (2012) Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol156: 259–264. doi: 10.1111/j.1365-2141.2011.08916.x 22017641
16. DeSimone J, Biel SI, Heller P, (1978) Stimulation of fetal hemoglobin synthesis in baboons by hemolysis and hypoxia. Proc Natl Acad Sci U S A75: 2937–2940. 96444
17. DeSimone J, Heller P, Adams JG, (1979) Hemopoietic stress and fetal hemoglobin synthesis: comparative studies in vivo and in vitro. Blood54: 1176–1181. 115514
18. DeSimone J, Heller P, Amsel J, Usman M, (1980) Magnitude of the fetal hemoglobin response to acute hemolytic anemia in baboons is controlled by genetic factors. J Clin Invest65: 224–226. doi: 10.1172/JCI109654 6765958
19. DeSimone J, Heller P, Biel M, Zwiers D, (1981) Genetic relationship between fetal Hb levels in normal and erythropoietically stressed baboons. Br J Haematol49: 175–183. 6170305
20. DeSimone J, Biel M, Heller P, (1982) Maintenance of fetal hemoglobin (HbF) elevations in the baboon by prolonged erythropoietic stress. Blood60: 519–523. 6178456
21. Lavelle D, DeSimone J, Heller P, Zwiers D, Hall L, (1986) On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation. Blood67: 1083–1089. 2420395
22. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med332: 1317–1322. doi: 10.1056/NEJM199505183322001 7715639
23. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ, (1997) Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood89: 1078–1088. 9028341
24. Ballas SK, Marcolina MJ, Dover GJ, Barton FB, (1999) Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br J Haematol105: 491–496. 10233426
25. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al. (1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood79: 2555–2565. 1375104
26. Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, et al. (2006) Hydroxyurea and sickle cell anemia: effect on quality of life. Health and Quality of Life Outcomes4: 59. doi: 10.1186/1477-7525-4-59 16942629
27. Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, et al. (2008) Hydroxyurea for the treatment of sickle cell disease. Evidence Report/technology Assessment: 1–95.
28. Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, et al. (2006) N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA296: 310–318. doi: 10.1001/jama.296.3.310 16849664
29. Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, et al. (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood99: 10–14. 11756146
30. Green NS, Manwani D, Qureshi M, Ireland K, Sinha A, Smaldone AM, (2016) Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Pediatric Blood & Cancer63: 2146–2153.
31. West MS, Wethers D, Smith J, Steinberg M, (1992) Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol45: 893–909. 1624972
32. Saraf S, Farooqui M, Infusino G, Oza B, Sidhwani S, Gowhari M, et al. (2011) Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. Br J Haematol153: 386–392. doi: 10.1111/j.1365-2141.2010.08479.x 21418176
33. van der Ploeg LH, Flavell RA, (1980) DNA methylation in the human gamma delta beta-globin locus in erythroid and nonerythroid tissues. Cell19: 947–958. 6247075
34. Mavilio F, Giampaolo A, Care A, Migliaccio G, Calandrini M, Russo G, et al. (1983) Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts. Proc Natl Acad Sci U S A80: 6907–6911. 6316333
35. Tagle DA, Koop BF, Goodman M, Slightom JL, Hess DL, Jones RT, (1988) Embryonic epsilon and gamma globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints. J Mol Biol203: 439–455. 3199442
36. DeSimone J, Heller P, Hall L, Zwiers D, (1982) 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A79: 4428–4431. 6181507
37. Ley TJ, DeSimone J, Anagnou NP, Keller GH, Humphries RK, Turner PH, et al. (1982) 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med307: 1469–1475. doi: 10.1056/NEJM198212093072401 6183586
38. Ley TJ, DeSimone J, Noguchi CT, Turner PH, Schechter AN, Heller P, et al. (1983) 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood62: 370–380. 6191799
39. Charache S, Dover G, Smith K, Talbot CC, Jr.Moyer M, Boyer S, (1983) Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl Acad Sci U S A80: 4842–4846. 6192443
40. Dover GJ, Charache S, Boyer SH, Vogelsang G, Moyer M, (1985) 5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood66: 527–532. 2411310
41. Lowrey CH, Nienhuis AW, (1993) Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. N Engl J Med329: 845–848. doi: 10.1056/NEJM199309163291205 7689171
42. Koshy M, DeSimone J, Molokie R, Dorn L, van der Galien T, Bressler L, (1998) Augmentation of fetal hemoglobin (HbF) levels by low-dose short-duration 5 '-aza-2-deoxycytidine (decitabine) administration in sickle cell anemia patients who had no HbF elevation following hydroxyurea therapy. Blood92: 30b–30b.
43. Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, et al. (2003) Effects of 5-aza-2 '-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood102: 3865–3870. doi: 10.1182/blood-2003-05-1738 12907443
44. Xu J, Bauer DE, Kerenyi MA, Vo TD, Hou S, Hsu YJ, et al. (2013) Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci U S A110: 6518–6523. doi: 10.1073/pnas.1303976110 23576758
45. Cui S, Kolodziej KE, Obara N, Amaral-Psarris A, Demmers J, Shi L, et al. (2011) Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic beta-type globin promoters in differentiated adult erythroid cells. Mol Cell Biol31: 3298–3311. doi: 10.1128/MCB.05310-11 21670149
46. Santi DV, Garrett CE, Barr PJ, (1983) On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell33: 9–10. 6205762
47. Covey JM, D'Incalci M, Tilchen EJ, Zaharko DS, Kohn KW, (1986) Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res46: 5511–5517. 2428479
48. Schermelleh L, Haemmer A, Spada F, Rosing N, Meilinger D, Rothbauer U, et al. (2007) Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation. Nucleic Acids Res35: 4301–4312. doi: 10.1093/nar/gkm432 17576694
49. Zauri M, Berridge G, Thezenas ML, Pugh KM, Goldin R, Kessler BM, et al. (2015) CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature524: 114–118. doi: 10.1038/nature14948 26200337
50. Almqvist H, Axelsson H, Jafari R, Dan C, Mateus A, Haraldsson M, et al. (2016) CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil. Nat Commun7: 11040. doi: 10.1038/ncomms11040 27010513
51. Olivieri NF, Saunthararajah Y, Thayalasuthan V, Kwiatkowski J, Ware RE, Kuypers FA, et al. (2011) A pilot study of subcutaneous decitabine in beta-thalassemia intermedia. Blood118: 2708–2711. doi: 10.1182/blood-2011-03-341909 21700776
52. Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, et al. (2015) Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest125: 1043–1055. doi: 10.1172/JCI78789 25621498
53. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, et al. (2004) Modification of hematopoietic stem cell fate by 5aza 2 ' deoxycytidine and trichostatin A. Blood103: 4102–4110. doi: 10.1182/blood-2003-07-2431 14976039
54. Hu Z, Negrotto S, Gu X, Mahfouz R, Ng KP, Ebrahem Q, et al. (2010) Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther9: 1536–1543. doi: 10.1158/1535-7163.MCT-10-0191 20501800
55. DeSimone J, Koshy M, Dorn L, Lavelle D, Bressier L, Molokie R, et al. (2002) Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood99: 3905–3908. 12010787
56. Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK, (2006) Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom20: 1117–1126. doi: 10.1002/rcm.2423 16523529
57. Liu Z, Liu S, Xie Z, Blum W, Perrotti D, Paschka P, et al. (2007) Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res35: e31. doi: 10.1093/nar/gkl1156 17264127
58. Camiener GW, Smith CG, (1965) Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol14: 1405–1416. 4956026
59. Neil GL, Moxley TE, Kuentzel SL, Manak RC, Hanka LJ, (1975) Enhancement by tetrahydrouridine (NSC-112907) of the oral activity of 5-azacytidine (NSC-102816) in L1210 leukemic mice. Cancer Chemother Rep59: 459–465. 54211
60. DeSimone J, Heller P, Molokie RE, Hall L, Zwiers D, (1985) Tetrahydrouridine, cytidine analogues, and hemoglobin F. Am J Hematol18: 283–288. 2579548
61. Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ, (2008) Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin Cancer Res14: 3529–3535. doi: 10.1158/1078-0432.CCR-07-4885 18519786
62. Ebrahem Q, Mahfouz R, Ng KP, Saunthararajah Y, (2012) High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget3: 1137–1145. doi: 10.18632/oncotarget.597 23087155
63. Riccardi R, Chabner B, Glaubiger DL, Wood J, Poplack DG, (1982) Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. Cancer Res42: 1736–1739. 6896013
64. Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, et al. (1991) Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)—a pilot study. Leukemia5: 991–998. 1961042
65. Wong PP, Currie VE, Mackey RW, Krakoff IH, Tan CT, Burchenal JH, et al. (1979) Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat Rep63: 1245–1249. 383291
66. Ho DH, Bodey GP, Hall SW, Benjamin RS, Brown NS, Freireich EJ, et al. (1978) Clinica, pharmacology of tetrahydrouridine. J Clin Pharmacol18: 259–265. 641214
67. Kreis W, Woodcock TM, Gordon CS, Krakoff IH, (1977) Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man. Cancer Treat Rep61: 1347–1353. 589600
68. Marsh JH, Kreis W, Barile B, Akerman S, Schulman P, Allen SL, et al. (1993) Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother Pharmacol31: 481–484. 8453688
69. Goldenthal EI, Cookson KM, Geil RG, Wazeter FX, (1974) Preclinical toxicologic evaluation of tetrahydrouridine (NSC-112907) in beagle dogs and rhesus monkeys. Cancer Chemother Rep35: 15–16.
70. Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, et al. (2012) Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood119: 1240–1247. doi: 10.1182/blood-2011-08-371690 22160381
71. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, et al. (2009) LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics4: 176–184. 19421002
72. Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, et al. (2015) Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest. 2;125(3):1043–55. doi: 10.1172/JCI78789 25621498
73. Santi DV, Norment A, Garrett CE, (1984) Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A81: 6993–6997. 6209710
74. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B, (2010) Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res38: 4313–4324. doi: 10.1093/nar/gkq187 20348135
75. Creusot F, Acs G, Christman JK, (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem257: 2041–2048. 6173384
76. Saunthararajah Y, (2013) Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology Am Soc Hematol Educ Program2013: 511–521. doi: 10.1182/asheducation-2013.1.511 24319226
77. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, et al. (2006) Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res12: 5777–5785. doi: 10.1158/1078-0432.CCR-06-0669 17020984
78. Jansen RS, Rosing H, Wijermans PW, Keizer RJ, Schellens JH, Beijnen JH, (2012) Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemotherapy and Pharmacol69: 1457–1466.
79. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, et al. (2011) Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol29: 2521–2527. doi: 10.1200/JCO.2010.34.4226 21576646
80. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, et al. (2009) Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res15: 3881–3888. doi: 10.1158/1078-0432.CCR-08-2196 19470736
81. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, et al. (2010) A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer116: 4043–4053. doi: 10.1002/cncr.25204 20564122
82. Goldschmidt N, Spectre G, Brill A, Zelig O, Goldfarb A, Rachmilewitz E, et al. (2008) Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thrombosis and Haemostasis100: 864–870. 18989531
83. Zhang D, Xu C, Manwani D, Frenette PS, (2016) Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood127: 801–809. doi: 10.1182/blood-2015-09-618538 26758915
84. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A, (2008) Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica93: 941–942. doi: 10.3324/haematol.12460 18460647
85. Gladwin MT, Kato GJ, (2008) Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!Haematologica93: 1–3. doi: 10.3324/haematol.12318 18166776
86. Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, et al. (2008) Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica93: 20–26. doi: 10.3324/haematol.11763 18166781
87. Whelihan MF, Zachary V, Orfeo T, Mann KG, (2012) Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood120: 3837–3845. doi: 10.1182/blood-2012-05-427856 22968460
88. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, et al. (1997) In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol98: 51–56. 9233563
89. Tripodi A, Cappellini MD, Chantarangkul V, Padovan L, Fasulo MR, Marcon A, et al. (2009) Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica94: 1520–1527. doi: 10.3324/haematol.2009.010546 19648162
90. Whelihan MF, Mooberry MJ, Zachary V, Bradford RL, Ataga KI, Mann KG, et al. (2013) The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells. J Thromb Haemost11: 2187–2189. doi: 10.1111/jth.12423 24119168
91. Chuncharunee S, Archararit N, Ungkanont A, Jootar S, Angchaisuksiri P, Bunyaratavej A, et al. (2000) Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis. J Med Assoc Thai83Suppl 1: S95–100.
92. Hathirat P, Mahaphan W, Chuansumrit A, Pintadit P, Sasanakul W, Isarangkura P, (1993) Platelet counts in thalassemic children before and after splenectomy. Southeast Asian J Trop Med Public Health24Suppl 1: 213–215.
93. Setty BN, Kulkarni S, Rao AK, Stuart MJ, (2000) Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood96: 1119–1124. 10910931
94. Setty BN, Kulkarni S, Dampier CD, Stuart MJ, (2001) Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. Blood97: 2568–2573. 11313243
95. Tefferi A, (2008) Platelet count in essential thrombocythemia: the more the better?Blood112: 3526–3527. doi: 10.1182/blood-2008-07-168807 18840727
96. van der Bom JG, Heckbert SR, Lumley T, Holmes CE, Cushman M, Folsom AR, et al. (2009) Platelet count and the risk for thrombosis and death in the elderly. J Thromb Haemost7: 399–405. doi: 10.1111/j.1538-7836.2008.03267.x 19143922
97. Swerdlow PS, (2006) Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program: 48–53. doi: 10.1182/asheducation-2006.1.48 17124039
98. de Haan G, Nijhof W, Van Zant G, (1997) Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. Blood89: 1543–1550. 9057635
99. Saunthararajah Y, Triozzi P, Rini B, Singh A, Radivoyevitch T, Sekeres M, et al. (2012) p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol39: 97–108. doi: 10.1053/j.seminoncol.2011.11.011 22289496
100. Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, et al. (2011) p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia25: 1739–1750. doi: 10.1038/leu.2011.159 21701495
101. Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, et al. (2012) CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia26: 244–254. doi: 10.1038/leu.2011.207 21836612
102. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, et al. (2012) Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells. Cancer Cell21: 430–446. doi: 10.1016/j.ccr.2011.12.029 22439938
103. Momparler RL, Cote S, Momparler LF, (2013) Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). Leuk Res. 37: 980–984. doi: 10.1016/j.leukres.2013.04.019 23660386
104. Velcheti V, Radivoyevitch T, Saunthararajah Y, (2017) Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. Am Soc Clin Oncol Educ Book37: 812–824. doi: 10.14694/EDBK_174175 28561650
105. Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, et al. (2011) Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res71: 1431–1441. doi: 10.1158/0008-5472.CAN-10-2422 21303982
106. Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, et al. (2012) Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo. Int J Cancer131: 18–29. doi: 10.1002/ijc.26320 21796622
107. Terse P, Engelke K, Chan K, Ling Y, Sharpnack D, Saunthararajah Y, et al. (2014) Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J of Toxicol33: 75–85.
108. Heinemann V, Plunkett W, (1989) Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. Biochem Pharmacol38: 4115–4121. 2688654
109. Dedrick RL, Forrester DD, Cannon JN, el-Dareer SM, Mellett LB, (1973) Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. Biochem Pharmacol22: 2405–2417. 4200888
110. Goren A, Simchen G, Fibach E, Szabo PE, Tanimoto K, Chakalova L, et al. (2006) Fine tuning of globin gene expression by DNA methylation. PLoS ONE1(1): e46. doi: 10.1371/journal.pone.0000046 17183675
111. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG, (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest74: 652–656. doi: 10.1172/JCI111464 6205021
112. Saunthararajah Y, Lavelle D, DeSimone J, (2004) DNA hypo-methylating agents and sickle cell disease. Brit J Haematol126: 629–636.
113. Scuto A, Kirschbaum M, Kowolik C, Kretzner L, Juhasz A, Atadja P, et al. (2008) The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood111: 5093–5100. doi: 10.1182/blood-2007-10-117762 18349321
114. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA, (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A107: 14639–14644. doi: 10.1073/pnas.1008522107 20679231
115. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, et al. (2010) Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res70: 4470–4480. doi: 10.1158/0008-5472.CAN-09-3028 20460513
116. Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C, et al. (2006) Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?Mol Cancer Res4: 563–573. doi: 10.1158/1541-7786.MCR-06-0111 16877702
117. Minucci S, Pelicci PG, (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer6: 38–51. doi: 10.1038/nrc1779 16397526
118. Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L, et al. (2012) DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res40: 4334–4346. doi: 10.1093/nar/gks031 22278882
119. Brenner C, Luciani J, Bizet M, Ndlovu M, Josseaux E, Dedeurwaerder S, et al. (2016) The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent. Oncotarget7: 58939–58952. doi: 10.18632/oncotarget.10624 27449289